Physician profile
Alexander Devries Brown
NPI 1043250343
$9,654.65
in general payments reported to CMS, 2019-2025
36 companies · $605 in 2025
The $605 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,684 · 2020: $521 · 2021: $233 · 2022: $665 · 2023: $1,883 · 2024: $2,064 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,552.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Biosciences INC. | $2,050.93 | 2019 | |
| Amgen INC. | $1,810.48 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,333.16 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $946.01 | 2019-2025 | |
| Pfizer INC. | $611.08 | 2019-2025 | |
| Janssen Biotech, INC. | $513.56 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $429.38 | 2019-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.34 | 2019-2024 | Cyltezo, Ofev |
| Glaxosmithkline, LLC. | $218.91 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $174.01 | 2019-2024 | Orencia |
| Mallinckrodt Hospital Products INC. | $164.61 | 2022-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $136.16 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $131.28 | 2023-2024 | Saphnelo |
| Lilly USA, LLC | $119.89 | 2022-2024 | Taltz |
| Celgene Corporation | $98.71 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $75.86 | 2020-2023 | Tymlos |
| Genentech USA, INC. | $73.86 | 2019-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $67.05 | 2024 | Lupkynis |
| Sobi, INC | $59.86 | 2019-2023 | |
| Organon LLC | $54.10 | 2022-2024 | |
| Daiichi Sankyo INC. | $35.39 | 2025 | Datroway |
| Emd Serono, INC. | $34.87 | 2021 | |
| Fresenius Kabi USA, LLC | $34.21 | 2023 | Idacio |
| Skeletal Dynamics INC | $32.72 | 2024 | Align, Implate, Geminus |
| Genzyme Corporation | $28.97 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.76 | 2023 | Purified Cortrophin Gel |
| Antares Pharma, INC. | $24.58 | 2020 | |
| Octapharma USA, INC. | $21.77 | 2023 | Octagam Immune Globulin (Human) |
| Kyowa Kirin, INC. | $19.38 | 2023 | Crysvita |
| Mylan Institutional INC. | $17.69 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.37 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.87 | 2022 | |
| Si-Bone, INC. | $16.78 | 2024 | |
| Horizon Therapeutics Plc | $16.05 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.